• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    4/23/24 8:06:32 AM ET
    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • ImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion.
    • Nuwellis (NASDAQ:NUWE) shares increased by 24.1% to $0.41. The market value of their outstanding shares is at $2.8 million.
    • VolitionRX (AMEX:VNRX) stock increased by 16.66% to $0.7. The company's market cap stands at $57.4 million.
    • Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 15.47% to $0.87. The market value of their outstanding shares is at $87.2 million.
    • Ontrak (NASDAQ:OTRK) stock moved upwards by 14.46% to $0.34. The market value of their outstanding shares is at $16.1 million.
    • NKGen Biotech (NASDAQ:NKGN) shares increased by 14.28% to $1.68. The market value of their outstanding shares is at $38.3 million.

    Losers

    • Abeona Therapeutics (NASDAQ:ABEO) stock declined by 45.7% to $4.0 during Tuesday's pre-market session. The market value of their outstanding shares is at $109.4 million.
    • OncoCyte (NASDAQ:OCX) stock declined by 16.34% to $2.1. The market value of their outstanding shares is at $28.0 million.
    • T2 Biosystems (NASDAQ:TTOO) shares fell 15.51% to $2.67. The company's market cap stands at $23.4 million.
    • Jaguar Health (NASDAQ:JAGX) stock declined by 14.46% to $0.15. The market value of their outstanding shares is at $44.2 million.
    • Phio Pharma (NASDAQ:PHIO) shares fell 14.28% to $0.71. The company's market cap stands at $3.2 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 10.42% to $1.29. The market value of their outstanding shares is at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $IBRX
    $JAGX
    $NKGN

    CompanyDatePrice TargetRatingAnalyst
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Abeona Therapeutics Inc.
    $ABEO
    6/2/2025$19.00Outperform
    Oppenheimer
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    Abeona Therapeutics Inc.
    $ABEO
    3/5/2025$16.00Outperform
    Oppenheimer
    ImmunityBio Inc.
    $IBRX
    1/10/2025$6.00Buy
    BTIG Research
    More analyst ratings

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunityBio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded ImmunityBio from Neutral to Overweight and set a new price target of $5.00

    5/20/25 8:01:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

    SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ("AD/PD™ 2026"), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually. The presentations will highlight a new integrated analysis of patient-level data from two previously completed Phase 1 studies evaluating troculeucel in patients with

    3/10/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/10/26 4:02:58 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/9/26 4:05:28 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    GC - Volition Diagnostics Plummer Nicholas covered exercise/tax liability with 5,867 shares, decreasing direct ownership by 1% to 414,270 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:30:25 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard covered exercise/tax liability with 3,321 shares, decreasing direct ownership by 1% to 277,941 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:31:18 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Commercial Officer Forterre Gael covered exercise/tax liability with 2,283 shares, decreasing direct ownership by 0.67% to 336,589 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/3/26 4:30:33 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

    CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will b

    3/3/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABEO
    $IBRX
    $JAGX
    $NKGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care